|

Iadademstat Clinical Trials

4 actively recruiting trials across 4 locations

▲ +1 trial since August 2026

Also known as: ORY 1001, ORY-1001, ORY-1001, RO7051790, RG 6016, RG6016 +3 more

Pipeline

Phase 1: 2Phase 2: 1Phase 1/2: 1

Top Sponsors

  • National Cancer Institute (NCI)2
  • Yale University1
  • OHSU Knight Cancer Institute1

Indications

  • Cancer4
  • Lung Cancer2
  • Blast Phase Myeloproliferative Neoplasm1
  • Accelerated Phase Myeloproliferative Neoplasm1
  • Extensive Stage Lung Small Cell Carcinoma1

Duarte, California1 trial

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

City of Hope Comprehensive Cancer Center

Phase 1/2

Irvine, California1 trial

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 2

New Haven, Connecticut1 trial

Iadademstat + SBRT With Atezo in ES-SCLC

Yale University

Phase 1

Portland, Oregon1 trial

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

OHSU Knight Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.